Ebola test vaccines appear safe in Phase 2 Liberian clinical trial
Liberia–U.S. partnership planning Phase 3 trial and study of Ebola survivors
Two experimental Ebola vaccines appear to be safe based on evaluation in more than 600 people in Liberia who participated in the first stage of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Phase 2/3 clinical trial, according to interim findings from an independent Data and Safety Monitoring Board review. Based on these findings, the study, which is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, may now advance to Phase 3 testing.
This page was last updated on Friday, January 21, 2022